Who are Lercanidipine/enalapril fixed combination's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Lotrel (amlodipine/benazepril), Amlodipine Besylate / Benazepril Hydrochloride.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/lercanidipine-enalapril-fixed-combination.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Lercanidipine/enalapril fixed combination — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Lercanidipine/enalapril fixed combination (Lercanidipine/enalapril fixed combination) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Calcium channel blocker / ACE inhibitor combination. Area: Cardiovascular.

marketed Calcium channel blocker / ACE inhibitor combination L-type voltage-gated calcium channels; Angiotensin-converting enzyme (ACE) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Lercanidipine/enalapril fixed combination (Lercanidipine/enalapril fixed combination) — Meir Medical Center. This fixed combination reduces blood pressure by blocking calcium channels in vascular smooth muscle (lercanidipine) and inhibiting angiotensin-converting enzyme (enalapril).

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Lercanidipine/enalapril fixed combination TARGET	Lercanidipine/enalapril fixed combination	Meir Medical Center	marketed	Calcium channel blocker / ACE inhibitor combination	L-type voltage-gated calcium channels; Angiotensin-converting enzyme (ACE)
Lotrel (amlodipine/benazepril)	Lotrel (amlodipine/benazepril)	Abbott	marketed	Calcium channel blocker / ACE inhibitor combination	L-type calcium channels (amlodipine); Angiotensin-converting enzyme (benazepril)
Amlodipine Besylate / Benazepril Hydrochloride	Amlodipine Besylate / Benazepril Hydrochloride	Dr. Reddy's Laboratories Limited	marketed	Calcium channel blocker / ACE inhibitor combination	L-type calcium channels; Angiotensin-converting enzyme (ACE)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Calcium channel blocker / ACE inhibitor combination class)

Abbott · 1 drug in this class
Dr. Reddy's Laboratories Limited · 1 drug in this class
Meir Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Lercanidipine/enalapril fixed combination — Competitive Intelligence Brief. https://druglandscape.com/ci/lercanidipine-enalapril-fixed-combination. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab